The cardiovascular effects, histamine release potential, and pharmacodynamics of rocuronium were determined in adult patients randomized to receive rapid (5 s) intravenous (IV) bolus doses of 600, 900, or 1200 ug/kg (2.0, 3.0, and 4.0 times the ED) with maintenance doses of 150 μg/kg. There were no statistically significant hemodynamic effects (heart rate, blood pressure, mean arterial pressure [MAP] or electrocardiogram [ECG) after administration of rocuronium. There were no increases in plasma histamine levels at 1, 3, and 5 min after the rapid IV bolus of rocuronium as determined by a new radioimmunoassay (RIA) with a sensitivity for histamine quantification of 0.05 ng/mL. Endotracheal intubation was successfully performed 6 min after rocuronium administration (and after plasma samples were obtained). The mean ± SD clinical durations of 600-, 900-, and 1200-ug/kg intubating doses of rocuronium under NO/O-sufentantl anesthesia were 45 ± 20 min, 66 ± 16 min, and 85 ± 22 min, respectively. We conclude that rocuronium can be administered safely over a wide range of doses (2-4 X ED), with minimum hemodynamic effects or histamine release.
This work was supported by a grant from Organon, Inc.
© 1994 International Anesthesia Research Society